Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27591303 | 0.85 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6335073 | 0.82 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL6334591 | 0.82 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL6429757 | 0.81 | CNR1 (0.62) | CNR1CNR2 | |
| SCHEMBL6333567 | 0.80 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6334720 | 0.80 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6334717 | 0.80 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6335175 | 0.80 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6334724 | 0.80 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL5807509 | 0.79 | CNR1 (0.81) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006060190-A2 | IMIDAZOLE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2006060203-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DEMENTIA AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-04-01 | — | — | US | claimed |
| WO-2006060190-A2 | IMIDAZOLE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060199-A2 | IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063691-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | CNR1 405/4885CNR2 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.